Abstract: SNDX-5613, commonly known as revumenib, is a first-in-class, orally bioavailable small molecule inhibitor targeting the menin-KMT2A protein-protein interaction. While revumenib has recently garnered regulatory approval for the treatment of relapsed or refractory acute leukemias harboring KMT2A rearrangements (KMT2Ar) or NPM1 mutations (NPM1mt), its therapeutic potential is actively being explored in broader oncological contexts, including solid tumors. By disrupting the menin-KMT2A complex, revumenib downregulates the aberrant expression of leukemogenic genes such as the HOXA cluster and MEIS1, thereby releasing differentiation blocks and inducing apoptosis in malignant cells. Despite its manageable safety profile and robust clinical efficacy, the emergence of acquired resistance through somatic MEN1 mutations and adverse events like QTc prolongation and differentiation syndrome present ongoing clinical challenges. Current research directions are expanding the application of revumenib into combination regimens and novel indications, notably including phase I/II trials for metastatic colorectal cancer and other solid tumors, highlighting its evolving role in precision oncology.
1. Introduction
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are heterogeneous malignancies characterized by distinct molecular and cytogenetic abnormalities. Among these, rearrangements in the lysine methyltransferase 2A (KMT2A) gene and mutations in the nucleophosmin 1 (NPM1) gene account for a significant proportion of acute leukemias and are historically associated with poor prognoses and high relapse rates [1][4]. SNDX-5613 (revumenib) has emerged as a breakthrough targeted therapy designed to inhibit the interaction between the scaffold protein menin and KMT2A [4]. Based on the pivotal AUGMENT-101 clinical trial, revumenib received approval from the U.S. Food and Drug Administration (FDA) in late 2024 for the treatment of relapsed or refractory (R/R) acute leukemia with KMT2A translocations and NPM1 mutations in adult and pediatric patients [5][6].
While the foundational development of revumenib has been deeply rooted in hematological malignancies, the overarching research direction for menin inhibition is expanding into the realm of solid tumors. The fundamental reliance of certain cancers on the menin-KMT2A epigenetic regulatory axis has prompted clinical investigations into the efficacy of SNDX-5613 for solid malignancies, representing a novel frontier for this targeted agent [3].
2. Pharmacological Activity
Revumenib has demonstrated robust pharmacological activity, primarily evaluated in heavily pretreated R/R acute leukemia populations. In the phase 1/2 AUGMENT-101 trial, revumenib monotherapy yielded an overall response rate (ORR) of 53% to 64% in patients with KMT2Ar or NPM1mt leukemias, with a composite complete remission (CR/CRh) rate ranging from 23% to 30% [1][5][11]. Furthermore, a significant proportion of responders (up to 78%) achieved measurable residual disease (MRD) negativity, allowing many to successfully bridge to allogeneic hematopoietic stem cell transplantation (allo-HSCT) [1][5].
Pharmacokinetically, revumenib is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme. Clinical trials have necessitated split-dose escalation designs to account for significant variations in drug metabolism when co-administered with strong CYP3A4 inhibitors, such as the antifungal agents posaconazole and voriconazole [10][13].
In alignment with the research direction of solid tumors, the pharmacological activity of SNDX-5613 is currently being evaluated beyond leukemias. A phase I/II clinical trial (NCT05731947) is actively investigating revumenib in combination with trifluridine/tipiracil and regorafenib for patients with relapsed/refractory, locally recurrent, or metastatic colorectal cancer (CRC) and other solid tumors [3]. This marks a critical expansion of revumenib's pharmacological utility into solid oncology.
3. Molecular Mechanism of Action
The molecular mechanism of revumenib centers on the epigenetic regulation of transcription. Menin, encoded by the MEN1 gene, is a nuclear scaffold protein that interacts with wild-type KMT2A and KMT2A fusion proteins to form an oncogenic chromatin-remodeling complex [4][13]. In KMT2Ar and NPM1mt leukemias, this complex aberrantly upregulates the transcription of the homeobox (HOXA) gene cluster and its critical cofactor, MEIS1 [8][13]. This hyperactivation enforces a differentiation block, driving the uncontrolled proliferation of leukemic blasts [7].
Revumenib acts as a highly selective, non-covalent small molecule inhibitor that binds directly to menin, physically disrupting its interaction with KMT2A [10]. By displacing the menin-KMT2A complex from chromatin, revumenib rapidly downregulates the expression of HOXA and MEIS1 [8]. This transcriptional silencing removes the maturation block, thereby inducing terminal differentiation and subsequent apoptosis of the malignant cells without disrupting normal hematopoiesis [9][13].
4. Structure-Activity Relationship (SAR)
Revumenib (SNDX-5613) was developed as a close structural analog of the preclinical compound VTP-50469 [9]. The molecule is designed to fit precisely into a highly conserved binding pocket located at the N-terminal of the menin protein, which is the essential interface for KMT2A binding [4][9].
A distinguishing feature of revumenib's SAR, compared to some other menin inhibitors in development, is its mechanism of target engagement. While certain menin inhibitors have been reported to induce the degradation of the menin protein itself, revumenib functions purely through competitive displacement; it occupies the binding pocket and prevents KMT2A association without causing menin degradation [9].
The structural specificity of revumenib is further highlighted by its vulnerability to point mutations within the menin binding pocket. Somatic mutations in the MEN1 gene that alter specific amino acid residues (e.g., M327I, M327V, G331R, G331D, and T349M) introduce steric clashes at the drug-binding interface. These structural alterations effectively block revumenib from binding to menin, yet they preserve the native menin-KMT2A interaction, allowing the oncogenic complex to remain active on chromatin [11].
5. Current Limitations
Despite its clinical success, the use of revumenib is constrained by specific toxicities and the rapid onset of acquired resistance. The most notable treatment-related adverse events (TRAEs) include:
Differentiation Syndrome (DS): As a direct consequence of its mechanism of action, revumenib induces rapid cellular differentiation, leading to DS in approximately 15% to 27% of patients [7][9]. Symptoms include leukocytosis, fever, hypoxia, and renal dysfunction. While potentially life-threatening, it is generally manageable with prompt administration of corticosteroids and hydroxyurea [4][8].
QTc Prolongation: Asymptomatic prolongation of the QTc interval is the primary dose-limiting toxicity, occurring in up to 53% of patients (with grade 3 or higher in 13% to 22.6%) [8][12]. This requires rigorous electrocardiographic monitoring, electrolyte repletion, and potential dose modifications [8].
Acquired Resistance: The durability of revumenib monotherapy is limited by the emergence of somatic MEN1 mutations. These mutations (such as M327 and G331 variants) can develop rapidly—sometimes within just two treatment cycles (approximately 8 weeks)—and are found in about 40% of patients experiencing disease progression [11]. This non-genetic and genetic clonal evolution necessitates the exploration of combination therapies.
6. Future Perspectives
The future clinical development of revumenib is focused on overcoming current limitations and expanding its therapeutic indications. To combat acquired resistance and improve long-term outcomes, revumenib is being aggressively evaluated in combination regimens. Trials such as the SAVE study (combining revumenib with decitabine/cedazuridine and venetoclax) and the BEAT AML study (combining revumenib with azacitidine and venetoclax) have shown highly promising synergistic efficacy, achieving ORRs of over 80% and high rates of MRD negativity [11][12]. Furthermore, revumenib is being investigated as a frontline therapy and as a post-transplant maintenance strategy to prevent relapse [8][11].
Crucially, aligning with the research direction of solid tumors, the therapeutic horizon for menin inhibitors is broadening. The ongoing phase I/II trial (NCT05731947) evaluating SNDX-5613 in combination with regorafenib and trifluridine/tipiracil for metastatic colorectal cancer and other solid tumors represents a pivotal step [3]. If the menin-KMT2A dependency observed in leukemias translates to solid tumor biology, revumenib could offer a novel epigenetic targeted approach for refractory solid malignancies, fundamentally reshaping its clinical trajectory.
